Companies›Healthcare›Healthcare›Healthcare Services
NSE:JLHL

JUPITER LIFE LINE HOSP L

Healthcare › Healthcare Services
₹255.50
at close · 27 Oct 2026
▲ 3.50 (+1.39%)

Latest filings

  1. Audio link shared for Q2 and H1 FY27 analyst call · Investor Communications
  2. September 2026 results: H1 revenue up 52%, profit up 57% · Compliance
  3. Q2 FY27 growth, Pune land purchase and 2,900-bed expansion plan · Investor Communications
All filings ↓
Ask Nexa about JUPITER LIFE LINE HOSP L

Snapshot

What the business is, and whether it's a good one at a fair price.

AI · written from filings

Operates a chain of multi-specialty hospitals across western and central India — Thane, Pune, Indore and the newly commissioned Dombivli — earning ₹1,499.8 crore in FY26 (+15.2% YoY). The Dombivli greenfield (500-bed capacity with 300 beds currently fitted out across 750,000 sq ft) opened in February 2026 two months ahead of schedule, and a 400-bed quaternary-care hospital is being set up on a one-lakh-sq-ft site in BKC Mumbai, with further projects in the pipeline at Pune South, Mira Road and Thane, taking the long-term bed-count target to roughly 3,000. Revenue is driven by inpatient and outpatient volumes — 10.8 lakh volumes in FY26, with Average Revenue Per Occupied Bed at ₹67,700 and Average Length of Stay of 3.87 days; insurance payers contributed 55.4% of FY26 revenue and government schemes 1%. The model is asset-heavy and expansion-driven: FY26 capex was deployed across Dombivli, BKC land, Pune and Mira Road, with gross debt at ~₹500 crore against cash of ~₹545 crore, leaving the balance sheet net cash positive. Other operating expenses (40.9% of revenue) and employee costs (17.1%) are the largest cost lines, followed by depreciation at 5.8%. A subsidiary has separately acquired Sulcus Private Limited to set up an IV fluids and pharmaceutical manufacturing facility near Ujjain with ₹35–40 crore of further investment planned.

Operating scale
Operational beds
1,259 bedsQ1 FY27
Average Revenue Per Occupied Bed (ARPOB)
₹67,700FY26
Average Length of Stay
3.87 daysFY26
Inpatient + outpatient volumes
10.8 lakhFY26
Dombivli greenfield
500-bed capacity, 300 fitted out, 750,000 sq ft, opened Feb 2026FY26
Long-term bed target
~3,000 beds (1,700 new beds across 4 greenfield projects at ~₹1.5 cr/bed)Long-term
Who pays it
Patients — primarily insured (55.4% of FY26 revenue), with a small government-scheme share (1%) and the remainder self-paying/cash and corporate patients in Mumbai, Pune and Indore catchments.
Biggest cost
Other operating expenses at 40.9% of revenue (medical consumables, drugs, outsourced services), followed by employee costs at 17.1% and depreciation at 5.8%.
Kind of business
Asset-heavy, owned-infrastructure multi-specialty hospital chain in active greenfield expansion.
Where it sits
Mumbai-anchored hospital operator with facilities in Thane, Pune and Indore and a 400-bed quaternary-care project coming up in BKC, Mumbai's most prominent healthcare address.
Market Cap
₹1,675 Cr
P / E (TTM)
8.9×
EV / EBITDA
5.6×
Div Yield
0.39%
Growth
—·
Revenue 5y CAGR
PAT — · EBITDA —
Quality
13.8%▲
ROCE (FY26)
ROE 12.9% · margin 25.7%
Leverage
0.33·
Debt / Equity · low
Net debt ₹454 Cr
Revenue FY24→FY26
1.4×▲
Margin −3.2 pts
₹1,070 Cr → ₹1,500 Cr
Cash conversion
1.12×▲
Operating cash ÷ profit · 3 yrs
₹636 Cr on ₹569 Cr
Moves on a normal day
0.88%·
Median daily move
Last 68 sessions · the yardstick for filing-day moves
Where it sits among 29 Hospital peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#4/30
P/B#2/24
ROCE#12/30
ROE#11/24
Debt / Equity#18/24
EBITDA margin#13/24
Revenue growth#13/23
Profit growth#18/21

Scorecard

Measured from the filed financials, judged against its Hospital peers · as of FY26 — not investment advice

Strengths
Returns on capital 13.8%
#12 of 30 in Hospital on the latest reported figures
Over 3 years it reported ₹569 Cr of profit and ₹636 Cr of operating cash — 1.12×
Profit is converting into cash
Concerns
Nothing flagged in the filed numbers.

Charts

How has the market priced it — with filings on the timeline?

JLHL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from JUPITER LIFE LINE HOSP L's filed financials and exchange disclosures

What does JUPITER LIFE LINE HOSP L do?

JUPITER LIFE LINE HOSP L is a Healthcare Services company listed on NSE and BSE, trading under the symbol JLHL.

Is JUPITER LIFE LINE HOSP L profitable?

Yes. Over the trailing twelve months JUPITER LIFE LINE HOSP L reported a net profit of ₹186 Cr on revenue of ₹1,558 Cr.

Does JUPITER LIFE LINE HOSP L pay a dividend?

Yes. The dividend yield is 0.39% at the current price. It paid out 3% of its profit as dividend in FY26.

Is JUPITER LIFE LINE HOSP L debt-free?

No. It reported borrowings of ₹509 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹454 Cr after cash. Debt stands at 0.33× equity. That is higher than 74% of its 24 Hospital peers.

Is JUPITER LIFE LINE HOSP L expensive compared with its peers?

On trailing P/E, JUPITER LIFE LINE HOSP L ranks 4 of 30 in Hospital — cheaper than 90% of them, against an industry median of 42.2×. This is a position, not a valuation judgement.

How much does the JUPITER LIFE LINE HOSP L share price move in a day?

On a typical session JUPITER LIFE LINE HOSP L moves 0.88% — that is the median absolute close-to-close move across its last 68 trading days. MarketPing measures each filing's price reaction against it.

Where can I track JUPITER LIFE LINE HOSP L's announcements?

Every NSE and BSE filing by JUPITER LIFE LINE HOSP L appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.